Announces a Record 25 Letters of Authorization to Proceed with Clinical Trials Covering 12 Novel Biological Molecules in 20 Tumor...
NantHealth will provide GPS Cancer molecular analysis to help UCSF better understand the molecular basis of metastatic breast cancer in...
Partnership enables oncologists in Singapore, Malaysia, Thailand, Vietnam and The Philippines to offer patients a new standard of care through GPS Cancer NantHealth expands global GPS Cancer launch...
Sistemas Medicos Nacionales becomes first international payer to cover GPS CancerTM for patients, bringing a new standard of cancer care...
Culver City, Calif. – June 2, 2017 — NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, announced today...
The NANT Cancer Vaccine, The First Simultaneous Combination of Off the Shelf Natural Killer Cells (NK) With Endogenous Adaptive Dendritic,...
CULVER CITY, Calif.--Mar. 10, 2017-- NantHealth, Inc. (NASDAQ-GS: NH),
Patrick Soon-Shiong, MD, CEO and founder of NantHealth, has been awarded the Intelligent Health Association (IHA) Special Recognition Award. The...
Throughout HIMSS 2017, NantHealth showcases its extensive Oncology Suite, Vitality Glowcap medication adherence system, its Connected Care solutions and much...
Led by the Division of Neurosurgery and Center for Data Driven Discovery at the Children's Hospital of Philadelphia, the Philadelphia...
Florida-based community oncologists leverage advanced molecular profile for decision support Doctors report that patients find hope in additional care options...
Patients and physicians can now access active clinical trials for various cancer types including lung, breast, leukemia and more through...